Albendazole-induced liver injury: A case report;Lesión hepática inducida por albendazol: Reporte de un caso

Colombia Medica

Volumn 44, Issue 2, 2013, Pages 118-120

  Ríos, David ^a   Restrepo, Juan C ^b  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b HOSPITAL PABLO TOBÓN URIBE   (Colombia)

Author keywords

Albendazole; Druginduced liver injury (DILI); Hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBENDAZOLE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LIVER CELL DAMAGE; LIVER FUNCTION; LIVER INJURY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PROTHROMBIN TIME;

EID: 84878581839     PISSN: 01208322     EISSN: 16579534     Source Type: Journal    
DOI: 10.25100/cm.v44i2.1021     Document Type: Article

References (15)

1. Vuitton DA. The WHO Informal Working Group on Echinococcosis. Coordinating Board of the WHO-IWGE. Parassitol. 1997; 39(4): 349-53.
2. Garcia HH, Evans CA, Nash TE, Takayanagui OM, White AC Jr, Botero D, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002; 15(4): 747-56.
3. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitol. 2000; 121(Suppl): S113-32.
4. Singthong S, Intapan PM, Wongsaroji T, Maleewong W. Randomized comparative trial of two high-dose Albendazole regimens for uncomplicated human strongyloidiasis. Southeast Asian J Trop Med Public Health. 2006; 37(Suppl 3): 32-4.
5. Brunton L, Lazo JS, Parker KL. Goodman Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006.
6. Maartens G, Sinxadi P. Pharmacology of anthelmintics: Albendazole, Mebendazole and praziquantel. CME. 2009; 274-6.
7. Horton J. Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations. Curr Opin Infect Dis. 2002; 15: 599-608.
8. Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, et al. Acute drug-induced hepatitis caused by albendazole. J Korean Med Sci Korea South. 2008; 23(5): 903-5.
9. Amoruso C, Fuoti M, Miceli V, Zito E, Celano MR, De Giorgi A, et al. Acute hepatitis as a side effect of albendazole: a pediatric case. Pediatr Med Chir. 2009; 31(6): 262-4.
10. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11(2): 272-6.
11. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanches C F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatol. 2001; 33: 123-30.
12. Ghabril M, Chalasani N, Bjornsson E. Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol. 2010; 26(3):222-6.
13. Gil GL, Rodríguez CF, Prieto J, Sánchez RJ, Brasa C, Aguilar L, et al. Randomized controlled trial of efficacy of albendazole in intra-abdominal hydatid disease. Lancet. 1993; 342: 1269-72.
14. Hussain S, Malik A, Khaja AR, Dass T, Naikoo Z. Role of Albendazole in the management of hydatid cyst liver. Saudi J Gastroenterol. 2011; 17(5): 343-7.
15. Bildik N, Cevik A, Altintaş M, Ekinci H, Canberk M, Gülmen M. Efficacy of preoperative Albendazole use according to months in hydatid cyst of the liver. J Clin Gastroenterol. 2007; 41(3):312-6.